Physician profile
Ram Chandra
NPI 1750349874
$2,016.28
in general payments reported to CMS, 2019-2025
21 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $92.38 · 2023: $200 · 2024: $491 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $354.43 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Astrazeneca Pharmaceuticals Lp | $250.30 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $218.65 | 2019-2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.01 | 2025 | Caplyta |
| Amgen INC. | $134.64 | 2020-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $129.63 | 2024-2025 | Kisunla, Zepbound, Jardiance |
| Vanda Pharmaceuticals INC. | $107.67 | 2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $88.05 | 2024-2025 | Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $84.88 | 2024-2025 | Auvelity |
| Dexcom, INC. | $81.43 | 2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $79.49 | 2019-2024 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $72.37 | 2019-2023 | |
| Pfizer INC. | $57.45 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $55.67 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $45.03 | 2024-2025 | Cobenfy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $26.04 | 2019 | |
| Sumitomo Pharma America, INC. | $18.52 | 2025 | Gemtesa |
| Lundbeck LLC | $18.39 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $14.52 | 2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.31 | 2025 | Jardiance |
| Melinta Therapeutics, LLC | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ram Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.